Upon analyzing over 3,000 people being treated
for Hepatitis C with pegylated interferon and
ribavirin, Mark Sulkowski and colleagues found this to be true even when ribavirin reduction or ESA administration was given to reduce anemia. In fact, the rates of achieving a sustained virological response were greater as the severity of the anemia increased.